-
Mashup Score: 4
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome and chronic myelomonocytic leukemia, vibecotamab appeared well-tolerated.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Early Signs of Activity Observed for Tagraxofusp Plus Decitabine in MDS, CMML | Docwire News - 2 day(s) ago
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
More #Heme Today reporting of new data for presentation at #ASH24: @Dr_MSU of @MDAndersonNews and colleagues bring evidence of #tagraxofusp plus #decitabine combo efficacy in #myelodysplasticsyndromes and #chronicmyelomonocyticleukemia. #MDS, #CMML https://t.co/2lwWbwd2qE
-
-
Mashup Score: 0
Azacitidine plus nivolumab especially demonstrated favorable efficacy compared to other combinations.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
#Heme Today reports new research in #myelodysplasticsyndromes from #ASH24: A study has compared doublet regimens of #azacitidine combined with #ipilimumab or #nivolumab, and triplet of all three agents for treatment-naive #MDS https://t.co/avqFUR7MMg
-
-
Mashup Score: 1CMML Drug Development Experts: Progress Requires Clear Differentiation From MDS | Docwire News - 4 day(s) ago
The US FDA conferred with experts on ways to improve CMML clinical trials and accelerate treatment advances in this disease.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
How can advances in #chronicmyelomonocyticleukemia agent development be accelerated? -- An expert panel convened by @US_FDA points out a need in clinical trials, practice to more clearly distinguish #CMML from #myelodysplasticsyndromes. #MDS, #Heme https://t.co/hSrfQOTGS1
-
-
Mashup Score: 0Phase II/III Pooled Data Analysis: Imetelstat Benefit in MDS Independent of Prior Therapy | Docwire News - 5 day(s) ago
Cohort patients had at least one prior intervention with luspatercept, lenalidomide, an HMA or ESA, or were ESA-ineligible.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
#Heme Today is covering #ASH24 !!! Coming up for presentation - #IMerge data analysis findings: #Imetelstat benefit in #myelodysplasticsyndromes is independent of prior #luspatercept, #lenalidomide, or #hypomethylatingagent tx. #MDS https://t.co/0yrQPgTo7r
-
-
Mashup Score: 2MDS Database Study Looks at Patient Quality of Life by Transfusion Dependency Status | Docwire News - 6 day(s) ago
The investigators compiled patients’ quality of life, social function, and physical scores, and assessed overall survival.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
On #Heme Today: In a #myelodysplasticsyndrome pt database study, researchers led by Rena Buckstein, MD, FRCPC, of @Sunnybrook evaluated pts' quality of life by change/persistence in transfusion dependence status with #MDS tx. https://t.co/wTcSJ57VTk
-
-
Mashup Score: 1Strong Safety, Nuanced Efficacy Results for Canakinumab in Previously-Treated MDS | Docwire News - 7 day(s) ago
Phase II trial results suggest limits to the IL-1β inhibitor’s efficacy by patient genetic complexity and SF3B1 mutation.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A phase II trial has evaluated the #IL1β inhibitor #canakinumab for previously-treated #myelodysplasticsyndromes: Safety strong, efficacy promising but with caveats by lower-risk vs higher-risk #MDS, pt genetic complexity, and #SF3B1 mutation #Heme https://t.co/7kkFISE65B
-
-
Mashup Score: 0Decitabine Plus Cedazuridine in TP53-Mutated MDS: Survival Compares Favorably With HMA | Docwire News - 8 day(s) ago
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
On #Heme Today in presentations at #ASH24 -- A look at the studies behind @US_FDA approval of #decitabine plus #cedazuridine for #TP53 mutated #myelodysplasticsyndromes. Does response to the combination vary by mutation type? #MDS https://t.co/OqkkkelRcV
-
-
Mashup Score: 1
Treatment with luspatercept led to decreases in red blood cell transfusion burden compared to epoetin alfa in patients with erythropoiesis-stimulating agent -naive LR-MDS.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
From the #COMMANDS trial for presentation at #ASH24: #Luspatercept tx has a reduced #RBC transfusion burden versus #epoetinalfa in pts with #erythropoiesisstimulatingagent-naive lower-risk #myelodysplasticsyndromes. #MDS, #Heme https://t.co/2EV8Dl17rr
-
-
Mashup Score: 3Early Signs of Activity Observed for Tagraxofusp Plus Decitabine in MDS, CMML | Docwire News - 9 day(s) ago
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
More #Heme Today reporting of new data for presentation at #ASH24: @Dr_MSU of @MDAndersonNews and colleagues bring evidence of #tagraxofusp plus #decitabine combo efficacy in #myelodysplasticsyndromes and #chronicmyelomonocyticleukemia. #MDS, #CMML https://t.co/2lwWbwd2qE
-
#Heme Today is continuing #ASH24 coverage: In new phase II data to be presented -- #Vibecotamab for #myelodysplasticsyndrome, #chronicmyelomonocyticleukemia, and other myeloid diseases shows encouraging safety. #MDS, #CMML https://t.co/CeA3LJHBG8